Twist Bioscience Showcases Next-Generation Sequencing Presentations at Virtual American Society for Human Genetics 2020 Annua...
October 29 2020 - 7:00AM
Business Wire
-- Presentations Detail Twist’s Methylation
Solution, a Cost-Effective Alternative to Single Nucleotide
Polymorphism (SNP) Microarray Technology and Data on the Infectious
Disease Product Line --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the presentation of
new customer and company data generated using the Twist Bioscience
target enrichment and library preparation products for
next-generation sequencing (NGS).
“The data presented at ASHG highlight the diverse applications
of our NGS target enrichment technology which can be applied to
consumer genomics, cancer detection, rare disease research, as well
as tracking viral evolution of infectious diseases,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We remain
focused on delivering optimal products for our customers to advance
research for the most pressing public health issues including
COVID-19, while at the same time continuing to develop synthetic
DNA based solutions to improve health and sustainability.”
In addition to customer presentations from Harvard Medical
School and Sema4, Twist Bioscience scientists will be presenting
posters on the following topics:
- Poster #3568: Targeted Sequencing-based Genotyping as a
Competitive Alternative to Genotyping Arrays. In this poster, a
case study showcasing the design of a Twist Custom Target Capture
Panel for the identification of hundreds of thousands of markers by
NGS. In this groundbreaking poster, data demonstrate that Twist can
apply its Custom Panel design algorithms to generate an
exceptionally large target enrichment panel with more than 240,000
single nucleotide polymorphism (SNP) with exceptional and
consistent performance. These data show that Twist is able to
produce a unified workflow to merge genotyping with exome
sequencing, leading to considerable cost savings while maintaining
high-quality data.
- Poster #2445: Tunability and Optimization Using the Twist
Fast Hybridization Target Enrichment System for DNA Methylation
Sequencing. This poster highlights Twist’s Targeted Methylation
Sequencing Solution and a novel and innovative way to generate
libraries used for methylation detection. While genetic sequencing
has allowed the ability to link sequence with a number of disease
states, other factors, including DNA methylation modifications on
adenines and cytosines, can affect gene expression through
epigenetic processes. Twist’s solution can be used in combination
with several different sized custom designed DNA methylation panels
and tuned to best fit timelines and preferred final picard metrics
while differentiating original methylation states.
- Poster #3293: A Target Enrichment Approach for Identifying
Infectious Disease. In this poster, we demonstrate Twist's
target enrichment systems as a sensitive and informative approach
combining library preparation and 30 minute Fast Hybridization for
detecting viral agents that can be RNA or DNA as well as single- or
double-stranded. The data show that our SARS-CoV-2 Research Panel
can detect the virus with as few as 10 copies of SARS-CoV-2 genome.
Extending our results beyond single infections, the data
demonstrate that Twist’s Respiratory Virus Research Panel
simultaneously detects multiple viral agents which can then be
sequenced with excellent coverage in a model of co-infection.
The posters will be available through the resources section of the Twist Bioscience
website.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 12, 2020. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029005467/en/
Investor Contact: Argot Partners Maeve Conneighton 212-600-1902
maeve@argotpartners.com
Media Contact: Angela Bitting 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024